Charles S. Berkman
2014 - Ligand Pharmaceuticals
In 2014, Charles S. Berkman earned a total compensation of $1.6M as Vice President and General Counsel at Ligand Pharmaceuticals, a 112% increase compared to previous year.
Compensation breakdown
| Non-Equity Incentive Plan | $115,711 |
|---|---|
| Option Awards | $958,516 |
| Salary | $288,938 |
| Stock Awards | $186,050 |
| Other | $5,700 |
| Total | $1,554,915 |
Berkman received $958.5K in option awards, accounting for 62% of the total pay in 2014.
Berkman also received $115.7K in non-equity incentive plan, $288.9K in salary, $186.1K in stock awards and $5.7K in other compensation.
Rankings
In 2014, Charles S. Berkman's compensation ranked 5,585th out of 13,032 executives tracked by ExecPay. In other words, Berkman earned more than 57.1% of executives.
| Classification | Ranking | Percentile |
|---|---|---|
All | 5,585 out of 13,032 | 57th |
Division Manufacturing | 1,999 out of 4,966 | 60th |
Major group Chemicals And Allied Products | 679 out of 1,686 | 60th |
Industry group Drugs | 527 out of 1,365 | 61st |
Industry Pharmaceutical Preparations | 409 out of 1,043 | 61st |
Source: SEC filing on April 14, 2017.
Berkman's colleagues
We found four more compensation records of executives who worked with Charles S. Berkman at Ligand Pharmaceuticals in 2014.